Avastin demonstrates overall survival in metastatic colorectal cancer patients with K-Ras gene status « Kinase News

Blogroll
Tags

AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Avastin demonstrates overall survival in metastatic colorectal cancer patients with K-Ras gene status

Posted on September 16, 2008 by crimsoncanary

Data presented at the European of Medical Oncology (ESMO) show Avastin (bevacizumab) is the only biologic to provide overall survival (OS) benefit when used as first-line treatment in combination with chemotherapy for patients with K-Ras wild type metastatic colorectal cancer (mCRC).

Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, kinase, Roche, VEGF

« Pazopanib demonstrates efficacy in Sarcoma and Ovarian cancer Pfizer ATM inhibitor CP466722 effective in sensitizing cells to irradiation »